ACR20 Best Abstracts - Day 2 Save
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
- Dr Curtis presents SEAM-RA RCT of withdrawal of ETN or MTX in patients on combo MTX/ETN therapy in sustained remission. 49.5% of ETN mono retained remission compared to 28.7% of MTX mono, and 52.9% who continued combo therapy. Abstract #939
- Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. Abstract #950
- Meta-analysis comparing JAKi (Tofa, Upa, Bari, Filg) of 20 RCTs 13,178 pts who failed DMARD/biologics: best efficacy and safety with UPA and Bari
- Efficacy of IVIG in Dermatomyositis Treatment 1st Placebo controlled RCT 79% responder by total improvement score vs. 44% Efficacy sustained thru wk 40 6% serious AE - included 4 thromboembolic events. Abstract # 0955
- Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. Abstract #952
- GUSelkumab 100 mg Q4W and Q8W efficacy consistent in PsA irrespective of baseline characteristics/domains. #Abstract 0908
ADD THE FIRST COMMENT
Disclosures
The author has no conflicts of interest to disclose related to this subject
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.